Eli Lilly and Company (NYSE:LLY) Shares Purchased by McAdam LLC

McAdam LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 21.4% in the 2nd quarter, HoldingsChannel reports. The fund owned 2,969 shares of the company’s stock after acquiring an additional 523 shares during the period. McAdam LLC’s holdings in Eli Lilly and Company were worth $2,688,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. LRI Investments LLC increased its stake in shares of Eli Lilly and Company by 2,063.5% during the 2nd quarter. LRI Investments LLC now owns 2,250 shares of the company’s stock valued at $2,037,000 after acquiring an additional 2,146 shares during the last quarter. Gilliland Jeter Wealth Management LLC grew its holdings in Eli Lilly and Company by 21.8% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 1,325 shares of the company’s stock valued at $1,200,000 after purchasing an additional 237 shares during the period. Colton Groome Financial Advisors LLC acquired a new position in Eli Lilly and Company during the second quarter worth approximately $468,000. EWA LLC raised its stake in Eli Lilly and Company by 12.2% during the second quarter. EWA LLC now owns 1,057 shares of the company’s stock worth $928,000 after purchasing an additional 115 shares during the period. Finally, Advisory Resource Group grew its stake in shares of Eli Lilly and Company by 3.1% during the 2nd quarter. Advisory Resource Group now owns 1,732 shares of the company’s stock valued at $1,569,000 after buying an additional 52 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.1 %

Shares of NYSE:LLY traded down $1.43 during midday trading on Friday, hitting $952.74. 2,063,309 shares of the company’s stock traded hands, compared to its average volume of 3,096,351. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The company has a market cap of $905.49 billion, a PE ratio of 140.32, a P/E/G ratio of 1.81 and a beta of 0.41. The firm’s fifty day moving average price is $886.32 and its two-hundred day moving average price is $813.81. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.55%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Analyst Ratings Changes

Several analysts have recently issued reports on LLY shares. Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, August 19th. Argus boosted their price objective on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. Finally, Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Two investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $956.88.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold 1,122,141 shares of company stock worth $991,938,411 in the last quarter. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.